Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
Identifieur interne : 001772 ( PubMed/Curation ); précédent : 001771; suivant : 001773Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
Auteurs : Anna K. Lugnér [Pays-Bas] ; Sido D. Mylius ; Jacco WallingaSource :
- Health economics [ 1099-1050 ] ; 2010.
Descripteurs français
- KwdFr :
- Analyse coût-bénéfice, Antiviraux (usage thérapeutique), Antiviraux (économie), Arbres de décision, Flambées de maladies (), Flambées de maladies (économie), Grippe humaine (traitement médicamenteux), Grippe humaine (transmission), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Modèles économétriques, Oséltamivir (usage thérapeutique), Oséltamivir (économie), Pays-Bas (épidémiologie), Transmission de maladie infectieuse ().
- MESH :
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux, Grippe humaine, Oséltamivir.
- économie : Antiviraux, Flambées de maladies, Grippe humaine, Oséltamivir.
- épidémiologie : Grippe humaine, Pays-Bas.
- Analyse coût-bénéfice, Arbres de décision, Flambées de maladies, Humains, Modèles économétriques, Transmission de maladie infectieuse.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Antiviral Agents (economics), Antiviral Agents (therapeutic use), Cost-Benefit Analysis, Decision Trees, Disease Outbreaks (economics), Disease Outbreaks (prevention & control), Disease Transmission, Infectious (prevention & control), Humans, Influenza, Human (drug therapy), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (transmission), Models, Econometric, Netherlands (epidemiology), Oseltamivir (economics), Oseltamivir (therapeutic use).
- MESH :
- chemical , economics : Antiviral Agents, Oseltamivir.
- chemical , therapeutic use : Antiviral Agents, Oseltamivir.
- geographic , epidemiology : Netherlands.
- drug therapy : Influenza, Human.
- economics : Disease Outbreaks, Influenza, Human.
- epidemiology : Influenza, Human.
- prevention & control : Disease Outbreaks, Disease Transmission, Infectious.
- transmission : Influenza, Human.
- Cost-Benefit Analysis, Decision Trees, Humans, Models, Econometric.
Abstract
Conventional (static) models used in health economics implicitly assume that the probability of disease exposure is constant over time and unaffected by interventions. For transmissible infectious diseases this is not realistic and another class of models is required, so-called dynamic models. This study aims to examine the differences between one dynamic and one static model, estimating the effects of therapeutic treatment with antiviral (AV) drugs during an influenza pandemic in the Netherlands. Specifically, we focus on the sensitivity of the cost-effectiveness ratios to model choice, to the assumed drug coverage, and to the value of several epidemiological factors. Therapeutic use of AV-drugs is cost-effective compared with non-intervention, irrespective of which model approach is chosen. The findings further show that: (1) the cost-effectiveness ratio according to the static model is insensitive to the size of a pandemic, whereas the ratio according to the dynamic model increases with the size of a pandemic; (2) according to the dynamic model, the cost per infection and the life-years gained per treatment are not constant but depend on the proportion of cases that are treated; and (3) the age-specific clinical attack rates affect the sensitivity of cost-effectiveness ratio to model choice.
DOI: 10.1002/hec.1485
PubMed: 19382106
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001772
Links to Exploration step
pubmed:19382106Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.</title><author><name sortKey="Lugner, Anna K" sort="Lugner, Anna K" uniqKey="Lugner A" first="Anna K" last="Lugnér">Anna K. Lugnér</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, Bilthoven, The Netherlands. anna.lugner@rivm.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, Bilthoven</wicri:regionArea></affiliation></author><author><name sortKey="Mylius, Sido D" sort="Mylius, Sido D" uniqKey="Mylius S" first="Sido D" last="Mylius">Sido D. Mylius</name></author><author><name sortKey="Wallinga, Jacco" sort="Wallinga, Jacco" uniqKey="Wallinga J" first="Jacco" last="Wallinga">Jacco Wallinga</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:19382106</idno><idno type="pmid">19382106</idno><idno type="doi">10.1002/hec.1485</idno><idno type="wicri:Area/PubMed/Corpus">001772</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001772</idno><idno type="wicri:Area/PubMed/Curation">001772</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001772</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.</title><author><name sortKey="Lugner, Anna K" sort="Lugner, Anna K" uniqKey="Lugner A" first="Anna K" last="Lugnér">Anna K. Lugnér</name><affiliation wicri:level="1"><nlm:affiliation>National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, Bilthoven, The Netherlands. anna.lugner@rivm.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, Bilthoven</wicri:regionArea></affiliation></author><author><name sortKey="Mylius, Sido D" sort="Mylius, Sido D" uniqKey="Mylius S" first="Sido D" last="Mylius">Sido D. Mylius</name></author><author><name sortKey="Wallinga, Jacco" sort="Wallinga, Jacco" uniqKey="Wallinga J" first="Jacco" last="Wallinga">Jacco Wallinga</name></author></analytic><series><title level="j">Health economics</title><idno type="eISSN">1099-1050</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (economics)</term><term>Antiviral Agents (therapeutic use)</term><term>Cost-Benefit Analysis</term><term>Decision Trees</term><term>Disease Outbreaks (economics)</term><term>Disease Outbreaks (prevention & control)</term><term>Disease Transmission, Infectious (prevention & control)</term><term>Humans</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (transmission)</term><term>Models, Econometric</term><term>Netherlands (epidemiology)</term><term>Oseltamivir (economics)</term><term>Oseltamivir (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Antiviraux (usage thérapeutique)</term><term>Antiviraux (économie)</term><term>Arbres de décision</term><term>Flambées de maladies ()</term><term>Flambées de maladies (économie)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (transmission)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Modèles économétriques</term><term>Oséltamivir (usage thérapeutique)</term><term>Oséltamivir (économie)</term><term>Pays-Bas (épidémiologie)</term><term>Transmission de maladie infectieuse ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Disease Transmission, Infectious</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Grippe humaine</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antiviraux</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Pays-Bas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Decision Trees</term><term>Humans</term><term>Models, Econometric</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse coût-bénéfice</term><term>Arbres de décision</term><term>Flambées de maladies</term><term>Humains</term><term>Modèles économétriques</term><term>Transmission de maladie infectieuse</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Conventional (static) models used in health economics implicitly assume that the probability of disease exposure is constant over time and unaffected by interventions. For transmissible infectious diseases this is not realistic and another class of models is required, so-called dynamic models. This study aims to examine the differences between one dynamic and one static model, estimating the effects of therapeutic treatment with antiviral (AV) drugs during an influenza pandemic in the Netherlands. Specifically, we focus on the sensitivity of the cost-effectiveness ratios to model choice, to the assumed drug coverage, and to the value of several epidemiological factors. Therapeutic use of AV-drugs is cost-effective compared with non-intervention, irrespective of which model approach is chosen. The findings further show that: (1) the cost-effectiveness ratio according to the static model is insensitive to the size of a pandemic, whereas the ratio according to the dynamic model increases with the size of a pandemic; (2) according to the dynamic model, the cost per infection and the life-years gained per treatment are not constant but depend on the proportion of cases that are treated; and (3) the age-specific clinical attack rates affect the sensitivity of cost-effectiveness ratio to model choice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19382106</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1050</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Health economics</Title><ISOAbbreviation>Health Econ</ISOAbbreviation></Journal><ArticleTitle>Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.</ArticleTitle><Pagination><MedlinePgn>518-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hec.1485</ELocationID><Abstract><AbstractText>Conventional (static) models used in health economics implicitly assume that the probability of disease exposure is constant over time and unaffected by interventions. For transmissible infectious diseases this is not realistic and another class of models is required, so-called dynamic models. This study aims to examine the differences between one dynamic and one static model, estimating the effects of therapeutic treatment with antiviral (AV) drugs during an influenza pandemic in the Netherlands. Specifically, we focus on the sensitivity of the cost-effectiveness ratios to model choice, to the assumed drug coverage, and to the value of several epidemiological factors. Therapeutic use of AV-drugs is cost-effective compared with non-intervention, irrespective of which model approach is chosen. The findings further show that: (1) the cost-effectiveness ratio according to the static model is insensitive to the size of a pandemic, whereas the ratio according to the dynamic model increases with the size of a pandemic; (2) according to the dynamic model, the cost per infection and the life-years gained per treatment are not constant but depend on the proportion of cases that are treated; and (3) the age-specific clinical attack rates affect the sensitivity of cost-effectiveness ratio to model choice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lugnér</LastName><ForeName>Anna K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control Netherlands, Epidemiology and Surveillance Unit, Bilthoven, The Netherlands. anna.lugner@rivm.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mylius</LastName><ForeName>Sido D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Wallinga</LastName><ForeName>Jacco</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Econ</MedlineTA><NlmUniqueID>9306780</NlmUniqueID><ISSNLinking>1057-9230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003663" MajorTopicYN="N">Decision Trees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018562" MajorTopicYN="N">Disease Transmission, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="N">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017059" MajorTopicYN="Y">Models, Econometric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19382106</ArticleId><ArticleId IdType="doi">10.1002/hec.1485</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001772 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001772 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:19382106
|texte= Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19382106" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |